Feasibility of EBUS-TBNA for the molecular characterization of non-small cell lung cancer-Reference-Cited by-同舟云学术

Feasibility of EBUS-TBNA for the molecular characterization of non-small cell lung cancer

Published:2024-06-17 Issue: Volume: Page:e20230193
ISSN:1806-3756
Container-title:Jornal Brasileiro de Pneumologia
language:en
Short-container-title:J Bras Pneumol.

Author:

Vaz Rodrigues1,2 Luis¹,Viegas3 Marta²,Cordovilla4 Rosa³,Taborda-Barata5 Luis⁴,Sousa6-9 Vitor⁵

Affiliation:

1. 1. Serviço de Pneumologia, Instituto Português de Oncologia, Francisco Gentil, Coimbra, Portugal. 2. Faculdade de Ciências da Saúde, Universidade da Beira Interior, Covilhã, Portugal.

2. 3. Serviço de Anatomia Patológica, Laboratório de Patologia Molecular, Instituto Português de Oncologia, Francisco Gentil, Coimbra, Portugal.

3. 4. Serviço de Pneumologia, Hospital Universitário de Salamanca, Salamanca, Espanha.

4. 5. Health Sciences Research Centre and UBIAir – CICS-UBI – Clinical & Experimental Lung Centre, Universidade da Beira Interior, Covilhã, Portugal.

5. 6. Instituto de Anatomia Patológica e Patologia Molecular, Faculdade de Medicina da Universidade de Coimbra, Coimbra, Portugal. 7. Research Center for Environment, Genetics and Oncobiology – CIMAGO –Faculdade de Medicina, Universidade de Coimbra, Coimbra, Portugal. 8. Centro de Pneumologia, Faculdade de Medicina, Universidade de Coimbra, Coimbra, Portugal. 9. Serviço de Anatomia Patológica, Hospitais da Universidade de Coimbra, Coimbra, Portugal.

Publisher

Sociedade Brasileira de Pneumologia e Tisiologia

Reference10 articles.

1. 1. Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, et al. Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022;20(5):497-530. https://doi.org/10.6004/jnccn.2022.0025

2. 2. Vilmann P, Clementsen PF, Colella S, Siemsen M, De Leyn P, Dumonceau JM, et al. Combined endobronchial and esophageal endosonography for the diagnosis and staging of lung cancer: European Society of Gastrointestinal Endoscopy (ESGE) Guideline, in cooperation with the European Respiratory Society (ERS) and the European Society of Thoracic Surgeons (ESTS) [published correction appears in Endoscopy. 2015 Jun;47(6):c1. Vasquez-Sequeiros, Enrique [corrected to Vazquez-Sequeiros, Enrique]]. Endoscopy. 2015;47(6):545-559. https://doi.org/10.1055/s-0034-1392040

3. 3. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011;6(2):244-285. https://doi.org/10.1097/JTO.0b013e318206a221

4. 4. Lindeman NI, Cagle PT, Aisner DL, Arcila ME, Beasley MB, Bernicker EH, et al. Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. Arch Pathol Lab Med. 2018;142(3):321-346. https://doi.org/10.5858/arpa.2017-0388-CP

5. 5. Leighl NB, Rekhtman N, Biermann WA, Huang J, Mino-Kenudson M, Ramalingam SS, et al. Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the study of lung cancer/association for molecular pathology guideline. J Clin Oncol. 2014;32(32):3673-3679. https://doi.org/10.1200/JCO.2014.57.3055